Hengrui Pharma and Braveheart Bio Unveil Promising Phase 2 Findings for Heart Drug HRS-1893 Hengrui Pharma and Braveheart Bio report positive Phase 2 trial results for HRS-1893, a promising treatment for obstructive hypertrophic cardiomyopathy, showcasing significant improvements.

Hengrui Pharma and Braveheart Bio Unveil Promising Phase 2 Findings for Heart Drug HRS-1893 #None #Hengrui_Pharma #Braveheart_Bio #HRS-1893

Braveheart Bio Strengthens Leadership with Emil deGoma, M.D. as CMO for Innovative Cardiovascular Therapeutics Braveheart Bio appoints Dr. Emil deGoma as Chief Medical Officer to lead clinical strategy and advance the development of BHB-1893 for heart diseases.

Braveheart Bio Strengthens Leadership with Emil deGoma, M.D. as CMO for Innovative Cardiovascular Therapeutics #USA #San_Francisco #Braveheart_Bio #BHB-1893 #Emil_deGoma

Braveheart Bio Announces Participation in Major Healthcare Conference for Future Innovations Braveheart Bio will participate in the TD Cowen 46th Annual Health Care Conference on March 2-4, 2026, in Boston to engage with investors.

Braveheart Bio Announces Participation in Major Healthcare Conference for Future Innovations #USA #San_Francisco #Hypertrophic_Cardiomyopathy #TD_Cowen #Braveheart_Bio

Braveheart Bio Strengthens Leadership Amid Global Phase 3 Development for Hypertrophic Cardiomyopathy Braveheart Bio has made key senior appointments to enhance its scientific and operational expertise as it gears up for a global Phase 3 trial in hypertrophic cardiomyopathy.

Braveheart Bio Strengthens Leadership Amid Global Phase 3 Development for Hypertrophic Cardiomyopathy #United_States #San_Francisco #Hypertrophic_Cardiomyopathy #Braveheart_Bio #BHB-1893

Braveheart Bio to Showcase Novel Therapies at J.P. Morgan Healthcare Conference Braveheart Bio is set to present its innovations in cardiac treatment at the prestigious J.P. Morgan Healthcare Conference, anticipated for January 2026.

Braveheart Bio to Showcase Novel Therapies at J.P. Morgan Healthcare Conference #United_States #San_Francisco #Hypertrophic_Cardiomyopathy #Braveheart_Bio #BHB-1893

Braveheart Bio Raises $185 Million to Revolutionize Hypertrophic Cardiomyopathy Treatment Braveheart Bio, a late clinical-stage biotech firm, has secured $185 million to enhance treatments for hypertrophic cardiomyopathy, aiming for patient-centered innovation.

Braveheart Bio Raises $185 Million to Revolutionize Hypertrophic Cardiomyopathy Treatment #USA #San_Francisco #HCM #Braveheart_Bio #BHB-1893

Hengrui Pharma Forms Exclusive Partnership with Braveheart Bio for Cardiovascular Innovation Hengrui Pharma has partnered with Braveheart Bio to develop the cardiac myosin inhibitor HRS-1893, marking a significant milestone in heart disease treatment.

Hengrui Pharma Forms Exclusive Partnership with Braveheart Bio for Cardiovascular Innovation #China #Shanghai #Hengrui_Pharma #Braveheart_Bio #HRS-1893